In vitro chemosensitivity testing of flavone acetic acid (LM975; NSC 347512) and its diethylaminoethyl ester derivative (LM985; NSC 293015) - PubMed (original) (raw)
In vitro chemosensitivity testing of flavone acetic acid (LM975; NSC 347512) and its diethylaminoethyl ester derivative (LM985; NSC 293015)
W A Schroyens et al. Eur J Cancer Clin Oncol. 1987 Aug.
Abstract
The antitumor effect of flavone acetic acid, LM975, and its diethylaminoethyl ester derivative, LM985, was studied in four human malignant cell lines [WiDr, a colon carcinoma; LICR (LON) HN-3, a tongue carcinoma; MCF7, a breast carcinoma; K-562, a leukemia] using a colorimetric assay based on the reduction of dimethylthiazol-2-yl-diphenyltetrazolium. The cell lines were exposed continuously for 4-6 days to drug concentrations ranging between 0.1 and 500 micrograms/ml. For LM975, the concentrations inhibiting the growth of the various cell lines by 50% were 200 +/- 10, 97 +/- 7, 171 +/- 16 and greater than 500 micrograms/ml for LICR (LON) HN-3, WiDr, MCF-7, and K-562, respectively. The corresponding concentrations for LM985 were 151 +/- 3, 36 +/- 4, 86 +/- 3 and 140 +/- 18 micrograms/ml, respectively. The difference between LM985 and LM975 was statistically significant for the WiDr and LICR (LON) HN-3 lines. We also evaluated the cytotoxic activity of the two agents on normal human marrow myeloid progenitor cells in a colony-forming assay. Continuous exposure to the drugs gave a dose-dependent inhibition. The concentrations inhibiting the growth by 50% were 76 +/- 31 micrograms/ml for LM975 and 134 +/- 41 micrograms/ml for LM985. One hour incubation with either compound had no toxic effect on the myeloid progenitor cells. In conclusion, LM975 and LM985 do not appear to have a specific cytotoxicity for tumor cells. Our results indicate that, in vitro, toxicity on bone marrow myeloid progenitor cells is concentration dependent. Considering the low plasma concentration found in man after i.v. administration of LM985, our observations correlate well with the absence of drug-induced myelosuppression in patients.
Similar articles
- Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid).
Bibby MC, Double JA, Phillips RM, Loadman PM. Bibby MC, et al. Br J Cancer. 1987 Feb;55(2):159-63. doi: 10.1038/bjc.1987.32. Br J Cancer. 1987. PMID: 3814485 Free PMC article. - Clinical and pharmacokinetic phase I trial with the diethylaminoester of flavone acetic acid (LM985, NSC 293015).
Dodion PF, Abrams J, Gérard B, Crespeigne N, Peeters B, Van Berchem C, Kenis Y. Dodion PF, et al. Eur J Cancer Clin Oncol. 1987 Jun;23(6):837-42. doi: 10.1016/0277-5379(87)90288-4. Eur J Cancer Clin Oncol. 1987. PMID: 3653200 - Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester).
Kerr DJ, Kaye SB, Graham J, Cassidy J, Harding M, Setanoians A, McGrath JC, Vezin WR, Cunningham D, Forrest G, et al. Kerr DJ, et al. Cancer Res. 1986 Jun;46(6):3142-6. Cancer Res. 1986. PMID: 3698028 - Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.
O'Dwyer PJ, Shoemaker D, Zaharko DS, Grieshaber C, Plowman J, Corbett T, Valeriote F, King SA, Cradock J, Hoth DF, et al. O'Dwyer PJ, et al. Cancer Chemother Pharmacol. 1987;19(1):6-10. doi: 10.1007/BF00296246. Cancer Chemother Pharmacol. 1987. PMID: 3545524 Review. - Multiple-pool cell lifespan model of hematologic effects of anticancer agents.
Krzyzanski W, Jusko WJ. Krzyzanski W, et al. J Pharmacokinet Pharmacodyn. 2002 Aug;29(4):311-37. doi: 10.1023/a:1020984823092. J Pharmacokinet Pharmacodyn. 2002. PMID: 12518707 Review.
Cited by
- Identification and induction of cytochrome P450s involved in the metabolism of flavone-8-acetic acid in mice.
Pham MH, Rhinn H, Auzeil N, Regazzetti A, Harami DE, Scherman D, Chabot GG. Pham MH, et al. Drug Metab Lett. 2011 Apr;5(2):73-84. doi: 10.2174/187231211795305221. Drug Metab Lett. 2011. PMID: 21457135 Free PMC article. - Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid.
Laws AL, Matthew AM, Double JA, Bibby MC. Laws AL, et al. Br J Cancer. 1995 Jun;71(6):1204-9. doi: 10.1038/bjc.1995.234. Br J Cancer. 1995. PMID: 7779712 Free PMC article. - Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512).
Bibby MC, Double JA, Loadman PM. Bibby MC, et al. Br J Cancer. 1988 Sep;58(3):341-4. doi: 10.1038/bjc.1988.215. Br J Cancer. 1988. PMID: 3179187 Free PMC article. - Flavone acetic acid induces a coagulopathy in mice.
Murray JC, Smith KA, Thurston G. Murray JC, et al. Br J Cancer. 1989 Nov;60(5):729-33. doi: 10.1038/bjc.1989.348. Br J Cancer. 1989. PMID: 2803949 Free PMC article. - Flavone acetic acid (LM-975; NSC-347512) activation to cytotoxic species in vivo and in vitro.
Chabot GG, Bissery MC, Gouyette A. Chabot GG, et al. Cancer Chemother Pharmacol. 1989;24(5):273-6. doi: 10.1007/BF00304757. Cancer Chemother Pharmacol. 1989. PMID: 2758556